Immunotherapy Strategies for Systemic Lupus Erythematosus: Focusing on CAR-T Cell Therapy

Area of Science:

• Immunology
• Cellular Therapy
• Rheumatology

Background:

• Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease with limited curative options.
• Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized cancer treatment and is now being explored for autoimmune conditions.
• Investigating novel therapeutic strategies is crucial for improving outcomes in SLE patients.

Purpose of the Study:

• To review the current evidence on CAR-T cell therapy for Systemic Lupus Erythematosus.
• To elucidate the pathological basis, mechanisms, and advancements of CAR-T therapy in SLE.
• To explore future directions and potential of CAR-T therapy for SLE.

Main Methods:

• Systematic review of recent literature (last five years) on CAR-T therapy for SLE.
• Analysis of preclinical and early clinical data.
• Synthesis of evidence regarding therapeutic mechanisms and outcomes.

Main Results:

• CAR-T therapy demonstrates potential by targeting pathogenic B cells or restoring immune tolerance in SLE.
• Preclinical and early clinical studies indicate efficacy in symptom mitigation.
• The therapy may induce sustained, drug-free remission, offering a paradigm shift from chronic management.

Conclusions:

• CAR-T cell therapy holds transformative potential for treating Systemic Lupus Erythematosus.
• Further research is needed to optimize targets and enhance safety.
• Larger clinical trials are essential to validate long-term efficacy.